Trial · NCT04663737
Results by group108
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 108
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) Within the CX-4945 Treatment Group | Group A | 9 | Participants | ||
| Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) Within the CX-4945 Treatment Group | Group B | 4 | Participants | ||
| Clinical Recovery Associated With COVID-19 Within the CX-4945 Treatment Group | Group A | 7 | 95% Confidence Interval 4 to 12 | Days | |
| Clinical Recovery Associated With COVID-19 Within the CX-4945 Treatment Group | Group B | 14 | 95% Confidence Interval 7 to 14 | Days | |
| Anti-Viral Activity of CX-4945 | Group A | Viral Clearance Day 8 / Negative | 4 | Participants | |
| Anti-Viral Activity of CX-4945 | Group B | Viral Clearance Day 8 / Negative | 6 | Participants | |
| Anti-Viral Activity of CX-4945 | Group A | Viral Clearance Day 8 / Positive | 3 | Participants | |
| Anti-Viral Activity of CX-4945 | Group B | Viral Clearance Day 8 / Positive | 2 | Participants | |
| Anti-Viral Activity of CX-4945 | Group A | Viral Clearance Day 8 / Inconclusive | 2 | Participants | |
| Anti-Viral Activity of CX-4945 | Group B | Viral Clearance Day 8 / Inconclusive | 0 | Participants | |
| Anti-Viral Activity of CX-4945 | Group A | Viral Clearance Day 8 / Not Evaluated | 1 | Participants | |
| Anti-Viral Activity of CX-4945 | Group B | Viral Clearance Day 8 / Not Evaluated | 2 | Participants | |
| Anti-Viral Activity of CX-4945 | Group A | Viral Clearance Day 14 (EOT) / Negative | 5 | Participants | |
| Anti-Viral Activity of CX-4945 | Group B | Viral Clearance Day 14 (EOT) / Negative | 7 | Participants | |
| Anti-Viral Activity of CX-4945 | Group A | Viral Clearance Day 14 (EOT) / Positive | 0 | Participants | |
| Anti-Viral Activity of CX-4945 | Group B | Viral Clearance Day 14 (EOT) / Positive | 1 | Participants | |
| Anti-Viral Activity of CX-4945 | Group A | Viral Clearance Day 14 (EOT) / Inconclusive | 2 | Participants | |
| Anti-Viral Activity of CX-4945 | Group B | Viral Clearance Day 14 (EOT) / Inconclusive | 1 | Participants | |
| Anti-Viral Activity of CX-4945 | Group A | Viral Clearance Day 14 (EOT) / Not Evaluated | 3 | Participants | |
| Anti-Viral Activity of CX-4945 | Group B | Viral Clearance Day 14 (EOT) / Not Evaluated | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04663737/results